Last reviewed · How we verify
Haloperidol-Haloperidol
At a glance
| Generic name | Haloperidol-Haloperidol |
|---|---|
| Also known as | Haldol |
| Sponsor | New York State Psychiatric Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer (PHASE2, PHASE3)
- Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer (PHASE2)
- Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care (PHASE2, PHASE3)
- Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department (PHASE3)
- Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy (PHASE2, PHASE3)
- Maternal And Infant Antipsychotic Study
- Do Antipsychotics Block Insulin Action in the Brain: is it a Class Effect? (PHASE4)
- Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the ED: A RCT (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Haloperidol-Haloperidol CI brief — competitive landscape report
- Haloperidol-Haloperidol updates RSS · CI watch RSS
- New York State Psychiatric Institute portfolio CI